Treatment Algorithm for Metastatic Renal Cell Carcinoma - Recommendations Based on Evidence and Clinical Practice

被引：14

作者：

Bergmann, Lothar ^{[1
]}

Beck, Jochaim ^{[2
]}

Bothe, Kathrin ^{[3
]}

Brinkmann, Olaf A. ^{[4
]}

Buse, Stephan ^{[5
]}

Goebell, Peter J. ^{[6
]}

Gruenwald, Viktor ^{[7
]}

Holzapfel, Konstantin ^{[8
]}

Kuebler, Hubert ^{[9
]}

Marschner, Norbert W. ^{[10
]}

Mickischk, Gerald ^{[11
]}

Schultze-Seemann, Wolfgang ^{[12
]}

Siebels, Michael ^{[13
]}

Siemer, Stephan ^{[14
]}

Stoerkel, Stephan ^{[15
]}

Gschwend, Juergen E. ^{[9
]}

机构：

[1] Univ Klin Frankfurt, Med Klin 2, D-60590 Frankfurt, Germany

[2] Univ Med Johannes Gutenberg Univ, Med Klin & Poliklin 3, D-55122 Mainz, Germany

[3] Univ Klinikum Schleswig Holstein, Klin Urol & Kinderurol, Kiel, Germany

[4] St Bonifatius Hosp, Klin Urol & Kinderurol, Lingen

[5] Alfried Krupp Hosp, Urol Klin, Essen, Germany

[6] Univ Klinikum Erlangen, Urol Klin, Erlangen, Germany

[7] Hannover Med Sch, Hannover, Germany

[8] Inst Rontgendiagnost, Munich, Germany

[9] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, D-80290 Munich, Germany

[10] Praxis Interdisziplinare Onkol & Hamatol, Freiburg, Germany

[11] Ctr Operat Urol Bremen, Bremen, Germany

[12] Univ Freiburg Klinikum, Freiburg, Germany

[13] Urol Pasing, Munich, Germany

[14] Univ Klinikum Saarlandes, Klin Urol & Kinderurol, Homburg, Germany

[15] HELIOS Klinikum Wuppertal, Inst Pathol, Wuppertal, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷 / 03期

关键词：

Renal cell cancer; mRCC; TKI; mTOR; VEGF; Therapy sequences; INTERFERON-ALPHA; DOUBLE-BLIND; SORAFENIB; TEMSIROLIMUS; BEVACIZUMAB; SUNITINIB; SURVIVAL; TRIAL;

D O I：

10.1159/000360179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Until a few years ago, the treatment options for metastatic renal cell cancer (mRCC) were very limited. The growing understanding of the molecular pathomechanisms underlying RCC allowed the development of new treatment approaches. Meanwhile, several approved target-oriented substances from different drug classes are available endothelial growth factor (VEGF) and VEGF receptor or mTOR inhibition is well documented by phase III trials and reflected biomarkers have been identified in mRCC so far to demonstrate a benefit by a specific compound in an individual patient. Meanwhile, the sequential use of 'targeted therapies' in mRCC has been established as standard treatment. The optimal sequence of available agents is still unclear. A German RCC expert panel discussed and developed an algorithm for the choices of first-and second-line treatment in mRCC based on established clinical criteria.

引用

页码：136 / 141

页数：6

共 26 条

[1]

[Anonymous], 2012, AUSW TUM NIER

[2]

[Anonymous], J CLIN ONCOL S7

[3]

[Anonymous], J CLIN ONCOL S7

[4] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[5] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[6] Treatment selection in metastatic renal cell carcinoma: expert consensus [J].

Escudier, Bernard ;

Szczylik, Cezary ;

Porta, Camillo ;

Gore, Martin .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (06) :327-337

[7] Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma [J].

Escudier, Bernard ;

Szczylik, Cezary ;

Hutson, Thomas E. ;

Demkow, Tomasz ;

Staehler, Michael ;

Rolland, Frederic ;

Negrier, Sylvie ;

Laferriere, Nicole ;

Scheuring, Urban J. ;

Cella, David ;

Shah, Sonalee ;

Bukowski, Ronald M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1280-1289

[8] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Warren, Mark A. ;

Golshayan, Ali Reza ;

Sahi, Chakshu ;

Eigl, Bernhard J. ;

Ruether, J. Dean ;

Cheng, Tina ;

North, Scott ;

Venner, Peter ;

Knox, Jennifer J. ;

Chi, Kim N. ;

Kollmannsberger, Christian ;

McDermott, David F. ;

Oh, William K. ;

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5794-5799

[9] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[10]

Hutson T, 2012, ESMO 2012

← 1 2 3 →